← All trials
NCT04641273
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 22, 2021
- Primary completion
- Jun 26, 2023
- Completion date
- Jul 24, 2023
- First posted
- Nov 23, 2020
- Last posted
- Dec 2, 2021
- Enrollment
- 441
- Arms / groups
- 7 / —
- Source
- AACT · ingestion pipeline
Sponsors
- BayerLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.